62
report
IMI Socio-economic Impact Assessment Expert Group
This Innovative Medicines Initiative (IMI) report demonstrates how the first projects launched by I
MI made concrete improvements to pharmaceutical research and development (R&D); leveraging funding; creating new knowledge and tools; and making Europ
+ Read More
article
FasterCures adds innovation experts as senior fellows
Washington, DC -- FasterCures, a center of the Milken Institute, is expanding its work by adding two
highly respected innovators— biopharmaceutical industry expert Bernard Munos and open science leader John Wilbanks— as senior fellows.
+ Read More
report
Landscape of Trust: Health Data Frameworks
The rapid advancement of the health technology landscape relies heavily on patient data.
report
Strengthening the Biomedical Innovation Ecosystem: A Scorecard for System Assessment
As patients, we often evaluate our interactions within the "system" of biomedical innovation with a
simple question: "Did it work for me?" This evaluation considers many issues, including whether the best treatments are accessible and available, how the
+ Read More
report
Achieving Health Equity: A Multi-Stakeholder Action Plan to Address Diversity across the Clinical Trials Enterprise and the Biomedical Research Ecosystem
Clinical trials have been used for decades as the primary way by which researchers determine if a n
ew treatment is safe and effective for human use.
+ Read More
report
Financing the Control of Tuberculosis
As of 2015, roughly one third of the world’s population, mostly in poorer countries, carried tuberc
ulosis bacteria in their system. Given the characteristics of airborne diseases like tuberculosis, coordination among national and international age
+ Read More
report
Advancing Tech-Enabled Health and Home Care
Over the last two-plus years, the Milken Institute Center for the Future of Aging has explored the
financial and care-delivery gaps in the long-term care ma
+ Read More
report
Targeting Tau — Our Hope to Solving the Dementia Crisis
In our systems-based review of the biomedical landscape supporting research of a cellular protein c
alled tau—a common culprit in a number of neurodegenerative diseases—we make the case that focused strategic investment in tau research and the , At present, no disease-modifying therapies for the pure tauopathies exist. Researchers are working to develop effective therapeutic agents, which include approaches such as decreasing the amount of tau within the brain., Symptomatic Interventions
At present, no disease-modifying therapies for the pure tauopathies exist.
+ Read More
video
Venture Philanthropy in Action: A Case Study of EB Research Partnership and ProQR
How are nonprofit organizations leveraging venture philanthropy to accelerate the development of t
reatments and cures?
+ Read More
video
Dec. 7 at 11:30 am ET | Pain Points and Potential for Cell and Gene Therapies
Cell and gene therapies have the potential to transform the lives of patients and their families.
As judged by patients' perspectives and experiences, how close are we to realizing this potential?
+ Read More
video
The Cost of Chronic Disease and the Future of Treatment
The increasing prevalence of chronic diseases—including diabetes, heart disease, and multiple type
s of cancer—is a global trend that has seen a sharp rise in the MENA region.
+ Read More
video
May 2 at 10:00 am PDT | Tipping Point for US Health-Care System Transformation
High costs and a rapidly aging population are forcing the US health-care system to innovate. The M
edicare program, under new leadership, has declared that all Medicare enrollees will be in value-based care models by 2030.
+ Read More